Stock ONC ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Market Closed - Toronto S.E.
Other stock markets
 03:59:40 2024-05-17 pm EDT 		5-day change 1st Jan Change
1.51 CAD -2.58% Intraday chart for Oncolytics Biotech Inc. -5.62% -15.64%
May. 15 Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call
May. 15 Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
MT
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
MT
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million
MT
Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09
MT
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer
MT
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
MT
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer
CI
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA
CI
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
MT
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain
MT
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million
MT
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
CI
Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
MT
Oncolytics Biotech Brief: Says Filed Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
MT
Oncolytics Biotech Initiating Enrollment Expansion of GOBLET Anal Cancer Cohort
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. News Oncolytics Biotech Inc.
  5. Highlights
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW